Eli Lilly investing $27B more in US manufacturing
Published On Feb 27, 2025, 11:20 AM
Eli Lilly announced an investment of $27 billion to expand its U.S. manufacturing capabilities, bringing its total investment to over $50 billion since 2020. This move aims to enhance domestic drug production and reduce reliance on foreign manufacturing for vital active pharmaceutical ingredients. The investment is expected to create approximately 3,000 skilled jobs and support an additional 10,000 construction jobs. Eli Lilly's CEO highlighted the company's confidence in future demand for various medicines, advocating for a stronger domestic manufacturing base in the pharmaceutical sector.
Stock Forecasts
LLY
Positive
Eli Lilly's substantial investment in U.S. manufacturing indicates a strategic move towards strengthening its supply chain, particularly in the current economic climate where companies are looking to reduce risks associated with overseas production. This is likely to enhance Eli Lilly's operational efficiency and revenue growth over time, which could positively impact investor confidence and stock performance.
Related News
Stock market today: Dow pops, Nasdaq slips as focus turns to CPI inflation report
Jan 14, 2025, 4:51 PM
Investors are weighing what a reported gradual rollout of Trump tariff hikes could mean for inflation and the Fed.
Wall Street Slams Hold Button in Run-Up to CPI: Markets Wrap
Jan 14, 2025, 11:24 AM
(Bloomberg) -- Stocks and bonds saw small moves, with Wall Street traders unwilling to make any significant bets as they await key inflation data for clues on path of Federal Reserve rates over the next few months.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyA Blueprint for Better Bike LanesAs E-Bikes Boom in NYC, Some Call for More RegulationsIn the run-up to Wednesday’s consumer price index, the S&P 500 was little changed after an earlier advance that came
FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next
Dec 19, 2024, 3:57 PM
The FDA decided the shortage for Eli Lilly's GLP-1 tirzepatide has finally come to an end.